CytomX Therapeutics, Inc. (FRA:6C1)
4.876
+0.470 (10.67%)
Last updated: Jan 28, 2026, 8:02 AM CET
CytomX Therapeutics Revenue
CytomX Therapeutics had revenue of $5.96M USD in the quarter ending September 30, 2025, a decrease of -82.16%. This brings the company's revenue in the last twelve months to $113.63M, down -10.26% year-over-year. In the year 2024, CytomX Therapeutics had annual revenue of $138.10M with 36.45% growth.
Revenue (ttm)
$113.63M
Revenue Growth
-10.26%
P/S Ratio
8.38
Revenue / Employee
$939.10K
Employees
121
Market Cap
811.47M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 138.10M | 36.89M | 36.45% |
| Dec 31, 2023 | 101.21M | 48.05M | 90.38% |
| Dec 31, 2022 | 53.16M | 15.85M | 42.48% |
| Dec 31, 2021 | 37.31M | -31.12M | -45.47% |
| Dec 31, 2020 | 68.43M | 41.53M | 154.36% |
| Dec 31, 2019 | 26.90M | -32.60M | -54.79% |
| Dec 31, 2018 | 59.50M | -12.12M | -16.92% |
| Dec 31, 2017 | 71.62M | 58.78M | 457.59% |
| Dec 31, 2016 | 12.85M | 6.90M | 116.21% |
| Dec 31, 2015 | 5.94M | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 888.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Paul Hartmann AG | 2.44B |
| FRoSTA Aktiengesellschaft | 652.00M |
| tonies SE | 510.38M |
| Maschinenfabrik Berthold Hermle AG | 469.42M |
| Südwestdeutsche Salzwerke AG | 347.96M |
| EUROKAI GmbH & Co. KGaA | 262.47M |
| Northern Data AG | 200.27M |
| Berliner Effektengesellschaft AG | 174.56M |